AzTrials
AzTrials

Apical PeriodontitisPhase 1/2NCT06764004

The Effect of Human Umbilical Cord Mesenchymal Stem Cells and Exosomes on the Healing of Postoperative Pain and Periapical Lesions in the Treatment of Apical Periodontitis: Randomized Controlled Clinical Study

A Phase 1/2 study testing Stem Cell Product and Bleeding and clots in people with Apical Periodontitis, run by TC Erciyes University at 1 site in Turkey (Türkiye).

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The main purpose of this study is to evaluate the effect of Mesenchymal Stem Cells (MSCs) isolated from the umbilical cord and exosomes derived from these cells on the success of the treatment in the regenerative endodontic treatment of necrotic open apex molar teeth. Read more about this study

Who is it for?
Ages 9 to 15 yearsHealthy volunteers can take part
Conditions the study is for
Apical Periodontitis
What is being tested?
Stem Cell Product and Bleeding and clots
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jan 2025to 1 May 2025
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 9 to 15 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Molar teeth with open apex
  • Teeth with apical periodontitis
  • Teeth for which prosthetic restoration is not planned
  • Patients between the ages of 9-15 without any significant health problems
  • Patients who are not accompanied by periodontal problems and whose oral hygiene is in good condition

Who cannot join

  • Individuals with systemic diseases and allergic reactions
  • Severely damaged teeth
  • Previous root canal treatment has been performed on the tooth.
  • Use of antibiotics, anti-inflammatory, and painkillers in the last two weeks
  • Teeth with cracks and broken lines

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

İpek ERASLAN AKYÜZ contact

+9 5385591409

ipekemamak@hotmail.com

Turkey (Türkiye)1 site
  • Erciyes University

    Melikgazi, Kayseri

    +9 352 438 06 57, dent@erciyes.edu.tr

Other trials in Turkey (Türkiye)

About this study

The main purpose of this study is to evaluate the effect of Mesenchymal Stem Cells (MSCs) isolated from the umbilical cord and exosomes derived from these cells on the success of the treatment in the regenerative endodontic treatment of necrotic open apex molar teeth.

Regenerative endodontic treatment aims to disinfect root canals and revascularize pulp tissue. Our goals in this study are; obtaining umbilical cord-derived MSCs, obtaining exosomes derived from umbilical cord MSCs, selecting patients with molar teeth with necrotic open apex and periapical lesion, initiation of regenerative endodontic treatment and disinfection of root canals, induction of bleeding in the periapical region and formation of a blood clot in the root canal in the 1st patient group, in the 2nd patient group, umbilical cord-derived MSCs were placed in the root canals without bleeding in the periapical region, in the 3rd patient group, placement of exosomes from umbilical cord-derived MSCs into the root canals without causing bleeding in the periapical region, it is the follow-up of patients at regular intervals for up to 1 year after treatment is completed.

Read the detailed description

Endodontic treatment of immature, permanent teeth is one of the most challenging situations encountered in endodontics. The dentin walls of the roots of these teeth are thin and fragile, making it difficult to properly clean, prepare and fill. In immature permanent teeth, pulp necrosis causes root development to stop and the apex to remain open. Etiology of pulp necrosis; It may be due to caries, trauma or the presence of dental anomalies (dens invaginatus and dens evaginatus). Today, there is a paradigm shift in the treatment of such cases from traditional apexification procedures to regenerative endodontic procedures. The aim of both treatments is; The aim is to cure apical pathology, eliminate symptoms, stimulate root development by closing the apical opening, and restore the functional adequacy of the pulp tissue. Regenerative endodontic therapy involves procedures designed to repair or replace damaged tooth structures or regenerate part of the pulp-dentin complex. Many studies have shown that this treatment can achieve positive results, leading to resolution of the patient's initial signs and symptoms, complete healing of periapical tissues, thickening of the root canal wall, and continued root maturation with apical closure. The success of regenerative endodontic treatments depends on the presence of three critical components: a- Mesenchymal stem cells that form the source of odontoblast-like cells, b- Growth factors required for the stimulation, differentiation and proliferation of mesenchymal stem cells (MSCs), and c- A suitable environment for the continuation of root development. A physical scaffolding that provides an environment. With this treatment, undifferentiated mesenchymal cells replace the dentin and pulp tissue and the development of the roots continues. In addition, a positive response to viability tests can be achieved in teeth by causing bleeding in the periapical tissues. In a study conducted by Lovelace et al., they revealed that a significant amount of stem cells could be stimulated by induction of bleeding in the periapical region after disinfection of root canals. Many case reports have demonstrated that regenerative endodontic procedures using blood clots show successful results. Nowadays, various researchers aim to create more current regenerative therapy procedures using new biomaterials for the regeneration of tissues. Many approaches can be combined using different stem cells, scaffolds and growth factors to regenerate or repair teeth and supporting tissues.

MSCs are multipotent cells with low immunogenic potential that can be isolated from tissues such as bone marrow, adipose tissue and umbilical cord. Bone marrow-derived MSCs have generally been used in many experimental and clinical studies, but obtaining these cells has some disadvantages such as requiring invasive procedures and a reduced proliferation and differentiation potential associated with donor age and concomitant diseases. In contrast, umbilical cord-derived MSCs are easily obtainable and have higher differentiation potential. The therapeutic potential of umbilical cord-derived stem cells to treat a wide variety of disorders has led to their increased use in the treatment of many diseases, including regenerative therapy and modulation of refractory autoimmune diseases. In a study by Sun et al. evaluating the effectiveness of human umbilical cord MSC infusion in children with autism spectrum disorder, improvements in autism symptoms were reported. In the study by Brizuela et al., in which the effectiveness of using allogeneic umbilical cord stem cells in the regenerative treatment of teeth with periapical lesions was evaluated, it was reported that there was a reduction in the size of the apical lesion and a positive response was obtained from the teeth in sensitivity tests.

Exosomes are extracellular vesicles with different sizes ranging from 30-200 nm in diameter. Exosomes have been found to be secreted by many cell types, including immune system cells, neuronal, epithelial, endothelial, embryonic cells, and MSCs. Exosomes may contain various types of vesicles, including microvesicles and apoptotic bodies. Similarly, recent studies on the effectiveness of MSC-derived exosomes have found that they may have advantageous effects in a variety of contexts, including respiratory, cartilage, kidney, heart and liver diseases, bone repair and cancer. In a review study by Hammouda et al., it was reported that the use of stem cell-derived exosomes in regenerative therapies could be a promising regenerative tool for dentin-pulp complex regeneration.

Considering the literature information compiled above, the aim of this study is to evaluate the effect of human umbilical cord MSCs and exosomes on the healing of postoperative pain and periapical lesions through clinical and radiographic examinations in the regenerative endodontic treatment of necrotic open apex molar teeth.

Being tested
Stem Cell Product, Bleeding and clots
Keywords
Regenerative endodontics, rejeneration, stem cell
Medical subject headings
Periapical Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Stem Cell ProductGenetic

    Human umbilical cord stem cells and exosomes will be used.

  • Bleeding and clotsBiological

    Exosomes obtained from human umbilical cord stem cells will be used

Study groups in NCT06764004
Study groupRoleWhat they receive
Stem cell groupExperimentalHuman umbilical cord stem cells will be used.
Receives: Genetic: Stem Cell Product
Exosome groupExperimentalExosomes obtained from umbilical cord stem cells will be used.
Receives: Genetic: Stem Cell Product
Bleeding groupExperimentalA clot will be formed by bleeding in the periapical region of the root canals.
Receives: Biological: Bleeding and clots

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of patients' postoperative pain with a questionnaire

    It indicates the achievement of outcome measures upon completion of the treatment administered to patients. Pain assessment will be made with the visual analog scale (VAS). A score between 0 and 100 will be given for pain evaluation. '0' indicates no pain, '100' indicates severe pain.

    Measured: 1-4 months

Secondary outcomes (1)
  1. Follow-up of patients with questionnaire their pain and symptoms at regular intervals for up to 1 year

    Completion of the follow-up period of patients after regenerative endodontic treatment indicates that the secondary outcome measures have been achieved. Pain assessment will be made with the visual analog scale (VAS). A score between 0 and 100 will be given for pain evaluation. '0' indicates no pain, '100' indicates severe pain.

    Measured: 1-12 mouths

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jan 2025
  2. Study start1 Jan 2025 (estimated)
  3. Primary completion1 Feb 2025 (estimated)
  4. Study completion1 May 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06764004
Sponsor's protocol ID
2025
Status last verified
Jan 2025
First submitted
22 Dec 2024
Last updated
8 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Stem Cell Product and Bleeding and clots in people with Apical Periodontitis, run by TC Erciyes University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 8 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact İpek ERASLAN AKYÜZ (+9 5385591409, ipekemamak@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of patients' postoperative pain with a questionnaire (time frame: 1-4 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in